Table 2.
Responder rates by OMERACT-OARSI (per-protocol set).
| Responder Rates by OMERACT-OARSI | Test Group (n = 128) n (%) |
Comparator Group (n = 128) n (%) |
|---|---|---|
| Week 13 | 83 (64.8) | 82 (64.1) |
| Comparison between groups | ||
| 95% CI for proportion difference | −0.109, 0.125 | |
| χ2 p-value | 0.8961 | |
| Week 26 | 74 (57.8) | 78 (60.9) |
| Comparison between groups | ||
| 95% CI for proportion difference | −0.152, 0.089 | |
| χ2 p-value | 0.6107 |
CI, confidence interval; OMERACT-OARSI, Outcome Measures in Rheumatology Clinical Trials–Osteoarthritis Research Society International; χ2, chi-squared test. Missing data up to week 26 post-injection were addressed by considering patients with a missing OMERACT-OARSI response efficacy endpoint regardless of adherence to treatment or early discontinuation.